deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05589896

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Sponsor: Ossium Health, Inc.

Conditions Acute Biphenotypic Leukemia Acute Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Undifferentiated Leukemia CLL (Chronic Lymphocytic Leukemia) Chronic Myeloid Leukemia (CML) Cutaneous T Cell Lymphomas (CTCL) Hodgkins Lymphoma MDS (Myelodysplastic Syndrome) Non-Hodgkin Lymphomas
Interventions Ossium HPC Marrow, Bone Marrow Transplant Post-transplant treatment Pre-transplant conditioning - Myeloablative (MAC) Pre-transplant conditioning - Reduced Intensity (RIC)
Updated 9 times since 2022 Last updated: Feb 20, 2026 Started: Aug 16, 2024 Primary completion: May 31, 2026 Completion: Mar 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05589896, this PHASE1/PHASE2 trial focuses on Acute Biphenotypic Leukemia and Acute Leukemia and remains actively recruiting participants. Sponsored by Ossium Health, Inc., it has been updated 9 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2022 – ~Dec 2023 · 13 months · monthly snapshotNot Yet Recruiting~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshotRecruiting~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotRecruiting~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshotRecruiting~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshotRecruiting~Jul 2025 – ~Feb 2026 · 7 months · monthly snapshotRecruiting~Feb 2026 – present · 5 months · monthly snapshotRecruiting

Change History

9 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Jul 2025 — Feb 2026 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Apr 2025 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Sep 2024 — Apr 2025 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 4 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  2. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Dec 2023 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Nov 2022 — Dec 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ossium Health, Inc.
Data source: Ossium Health, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations